{"title":"Professor Brian Leonard: Former Editor-in-Chief of Human Psychopharmacology","authors":"David S. Baldwin","doi":"10.1002/hup.2894","DOIUrl":null,"url":null,"abstract":"<p>‘<i>Ní bheidh a leithéid ann arís</i>’ (‘we won't see his like again’). Thus concluded the warm tribute to Professor Brian Leonard, posted on the British Association for Psychopharmacology website, on the sad news of his passing, after a short illness, in the final week of 2023 (see www.bap.org.uk). Brian was a former President of both the BAP and the Collegium Internationale Neuropsychopharmacologicum (CINP) and served as Editor-in-Chief of <i>Human Psychopharmacology</i> between 1994 and 1999 (succeeding the Founding Editor Guy Edwards, whose obituary was published last year: see Cowen, <span>2023</span>). During his Editorship, the journal flourished in terms of its scientific content, international contributors, readership and impact.</p><p>Born in 1936, Brian became a leading figure in psychopharmacological research, education and training, over 50 years. After working at Nottingham University (1962–1968), and in the pharmaceutical industry (1968–1974, first at ICI Ltd, then Organon Laboratories), he became Founding Professor and Head of the Department of Pharmacology at University College Galway in 1974, continuing there until 1999, when he ‘retired’. He held Professor Emeritus status at the University of Galway, and a Visiting Professorship at the University of Maastricht from 2002, and an Honorary Professorship at Ludwig Maximilian University, Munich since 2007. He continued publishing scientific articles until the final months of 2023. His wide-ranging and influential research encompassed studies of anxiolytic and antidepressant compounds, the neurobiology of affective disorders, alcohol use disorders, and dementia, and he was an early pioneer in the realm of psychoneuroimmunology.</p><p>His former colleagues draw attention to his pioneering research in the development and characterisation of animal models of depression (most notably the olfactory bulbectomy model), and in preclinical studies of the pharmacology of antidepressants, anxiolytics, and other psychotropics: and his major contributions to investigating biomarkers of major psychiatric disorders, the metabolic syndrome in depression and schizophrenia, and in psychoneuroimmunology, where he was one of the first to recognise, investigate, and promote the importance of the brain-immune axis in depression and schizophrenia. He received the BAP Lifetime Achievement Award in 2008.</p><p>Brian was a truly inspirational lecturer, combining his extensive knowledge of pharmacology with panache and cheeky humour, encouraging many to pursue careers in clinical and experimental psychopharmacology and translational and applied neuroscience. After notional ‘retirement’ he travelled widely, in particular to low and middle income countries in Africa and Asia, lecturing to international colleagues and inspiring the emerging generations of academic and clinical researchers. He received the CINP Arvid Carlsson medal for education in 2012. In addition, Brian had a lifelong passion for challenging socioeconomic disadvantage, discrimination and other societal injustices, and would engage in insightful and lively political discussions whenever needed.</p><p>Brian kindly supported my research and clinical interests in anxiety and depression at a pivotal career stage; and later encouraged me to become Editor of this journal. He also invited me to contribute to his periodic psychopharmacology masterclasses in Dublin, and his lively and interactive CINP seminars in Athens, Cape Town, and Colombo, Sri Lanka. It has been wonderful to hear from many attendees at these events how they were captivated and inspired by Brian's social commitment, engaging delivery, and compendious knowledge. Indeed, he will be missed.</p>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 2","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hup.2894","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
‘Ní bheidh a leithéid ann arís’ (‘we won't see his like again’). Thus concluded the warm tribute to Professor Brian Leonard, posted on the British Association for Psychopharmacology website, on the sad news of his passing, after a short illness, in the final week of 2023 (see www.bap.org.uk). Brian was a former President of both the BAP and the Collegium Internationale Neuropsychopharmacologicum (CINP) and served as Editor-in-Chief of Human Psychopharmacology between 1994 and 1999 (succeeding the Founding Editor Guy Edwards, whose obituary was published last year: see Cowen, 2023). During his Editorship, the journal flourished in terms of its scientific content, international contributors, readership and impact.
Born in 1936, Brian became a leading figure in psychopharmacological research, education and training, over 50 years. After working at Nottingham University (1962–1968), and in the pharmaceutical industry (1968–1974, first at ICI Ltd, then Organon Laboratories), he became Founding Professor and Head of the Department of Pharmacology at University College Galway in 1974, continuing there until 1999, when he ‘retired’. He held Professor Emeritus status at the University of Galway, and a Visiting Professorship at the University of Maastricht from 2002, and an Honorary Professorship at Ludwig Maximilian University, Munich since 2007. He continued publishing scientific articles until the final months of 2023. His wide-ranging and influential research encompassed studies of anxiolytic and antidepressant compounds, the neurobiology of affective disorders, alcohol use disorders, and dementia, and he was an early pioneer in the realm of psychoneuroimmunology.
His former colleagues draw attention to his pioneering research in the development and characterisation of animal models of depression (most notably the olfactory bulbectomy model), and in preclinical studies of the pharmacology of antidepressants, anxiolytics, and other psychotropics: and his major contributions to investigating biomarkers of major psychiatric disorders, the metabolic syndrome in depression and schizophrenia, and in psychoneuroimmunology, where he was one of the first to recognise, investigate, and promote the importance of the brain-immune axis in depression and schizophrenia. He received the BAP Lifetime Achievement Award in 2008.
Brian was a truly inspirational lecturer, combining his extensive knowledge of pharmacology with panache and cheeky humour, encouraging many to pursue careers in clinical and experimental psychopharmacology and translational and applied neuroscience. After notional ‘retirement’ he travelled widely, in particular to low and middle income countries in Africa and Asia, lecturing to international colleagues and inspiring the emerging generations of academic and clinical researchers. He received the CINP Arvid Carlsson medal for education in 2012. In addition, Brian had a lifelong passion for challenging socioeconomic disadvantage, discrimination and other societal injustices, and would engage in insightful and lively political discussions whenever needed.
Brian kindly supported my research and clinical interests in anxiety and depression at a pivotal career stage; and later encouraged me to become Editor of this journal. He also invited me to contribute to his periodic psychopharmacology masterclasses in Dublin, and his lively and interactive CINP seminars in Athens, Cape Town, and Colombo, Sri Lanka. It has been wonderful to hear from many attendees at these events how they were captivated and inspired by Brian's social commitment, engaging delivery, and compendious knowledge. Indeed, he will be missed.
期刊介绍:
Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal:
-All aspects of clinical psychopharmacology-
Efficacy and safety studies of novel and standard psychotropic drugs-
Studies of the adverse effects of psychotropic drugs-
Effects of psychotropic drugs on normal physiological processes-
Geriatric and paediatric psychopharmacology-
Ethical and psychosocial aspects of drug use and misuse-
Psychopharmacological aspects of sleep and chronobiology-
Neuroimaging and psychoactive drugs-
Phytopharmacology and psychoactive substances-
Drug treatment of neurological disorders-
Mechanisms of action of psychotropic drugs-
Ethnopsychopharmacology-
Pharmacogenetic aspects of mental illness and drug response-
Psychometrics: psychopharmacological methods and experimental design